drugset
drugset / Trial / NCT02897856

Efficacy and Safety of Intramuscular Midazolam Compared to Buccal Midazolam in Pediatric Seizures

NCT02897856 ↗

Phase 4 Completed 150 enrolled Hamad Medical Corporation
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The goal of this study is to prove that intramuscular midazolam is more effective than buccal midazolam in cessation of seizure activity with comparable side effects.

Timeline

Start
2016-09
Primary completion
2018-11
Completion
2018-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator Midazolam Small molecule 0.25 mg/kg Other
Comparator Midazolam Small molecule 0.3 mg/kg Other

Indications

epilepsy